EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares stood at 1.28 million during the last session, with the company’s beta value hitting 1.71. At the close of trading, the stock’s price was $4.57, to imply an increase of 10.65% or $0.44 in intraday trading. The EYPT share’s 52-week high remains $23.65, putting it -417.51% down since that peak but still an impressive 10.5% since price per share fell to its 52-week low of $4.09. The company has a valuation of $314.09M, with an average of 0.98 million shares in intraday trading volume over the past 10 days and average of 846.49K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for EyePoint Pharmaceuticals Inc (EYPT), translating to a mean rating of 1.08. Of 4 analyst(s) looking at the stock, 0 analyst(s) give EYPT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
After registering a 10.65% upside in the last session, EyePoint Pharmaceuticals Inc (EYPT) has traded red over the past five days. The 5-day price performance for the stock is -14.90%, and -37.82% over 30 days. With these gigs, the year-to-date price performance is -38.66%. Short interest in EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) saw shorts transact 10.83 million shares and set a 13.37 days time to cover.
The extremes give us $22 and $22 for target low and target high price respectively. As such, EYPT has been trading -381.4% off suggested target high and -381.4% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 15.65% for the past 5-year period. While 2025 is set for a -22.68% return in earnings, projections for the next 5 years are at 0.67% annually.
EYPT Dividends
EyePoint Pharmaceuticals Inc has its next earnings report out on 2025-Mar-04. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
EyePoint Pharmaceuticals Inc insiders hold 1.16% of total outstanding shares, with institutional holders owning 109.63% of the shares at 110.92% float percentage. In total, 109.63% institutions holds shares in the company, led by CORMORANT ASSET MANAGEMENT, LP. As of 2024-06-30, the company held over 8.32 million shares (or 15.6467% of shares), all amounting to roughly $72.43 million.
The next major institution holding the largest number of shares is SUVRETTA CAPITAL MANAGEMENT, LLC with 5.18 million shares, or about 9.7279% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $45.03 million.
We also have Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the EyePoint Pharmaceuticals Inc (EYPT) shares. Going by data provided on Jan 31, 2025 , Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund holds roughly 2.04 shares. This is just over 2.97% of the total shares, with a market valuation of $9.32 million. Data from the same date shows that the other fund manager holds a little less at 1.99, or 2.89% of the shares, all valued at about 9.09 million.
